Our Doctors
Scott G. Foxman, M.D.
Founder and President
Retinal and Ophthalmic Consultants, P.C.
Retina Specialist
OFFICE LOCATIONS:
1500 Tilton Road, Northfield, NJ 08225
2466 East Chestnut Avenue, Vineland, NJ 08361
211 South Main Street, Cape May Court House, NJ 08210
PROFESSIONAL EXPERIENCE:
1986 - Present Founder, President Retinal and Ophthalmic Consultants, P.C.
EDUCATION:
1973 - 1979 B.A. Boston University Medical Honors Program, Boston University
1975 - 1979 M.D. Boston University Medical Honors Program, Boston University
POSTDOCTORAL RESEARCH:
1979 National Eye Institute
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
1979 - 1980 Intern in Medicine, Jackson Memorial Hospital, Miami
1980 - 1983 Resident in Ophthalmology University of Minnesota, Minneapolis
1983 - 1985 Fellowship, Vitreo-retinal Diseases
Jules Stein Eye Institute, UCLA,
Los Angeles
FACULTY APPOINTMENT:
1983 - 1985 Visiting Lecturer Jules Stein Eye Institute University of California
1986 - Present Courtesy
Scheie Eye Institute
University of Pennsylvania
School of Medicine
1986 - 1996 Associate Attending Ophthalmologist Division of Ophthalmology
Atlantic Regional Medical Center
1997 - Present Chief, Division of Ophthalmology Atlantic Regional Medical Center
1986 - Present Assistant Attending Ophthalmologist Division of Ophthalmology Shore Memorial Hospital
SPECIALTY CERTIFICATION:
1979 - Diplomat of The National Board of Medical Examiners
1984 - Diplomat of The American Board of Ophthalmology
LICENSURE: Pennsylvania, New Jersey, California
AWARDS AND HONORS:
PROFESSIONAL SOCIETIES:
| National Societies | American Society of Retina Specialists |
|
| Local Societies | Medical Society of New Jersey |
CLINICAL STAFF APPOINTMENTS
- Atlantic Regional Medical Center
- Shore Medical Center
- Betty Bacharach Rehabilitation Hospital
- Scheie Eye Institute
ACADEMIC APPOINTMENTS
- University of Penn
- Courtesy Staff
BOARD POSITIONS:
-
Past President
Atlantic County Medical Society -
Past President
Lions Club Vision Care Center
CHARITABLE POSITIONS:
-
Chairman
Leukemia Lymphoma Regatta, 2015 -
Co-Chairman
Leukemia Lymphoma Regatta, 2017 - Passed Business Editor
American Society of Retina Specialists -
Ballantine, E., Foxman, S., Gorden, P., Roth, J.: Rarity of Diabetic Retinopathy in Patients with Acromegaly. Arch. Intern. Med. 1981; 141:1625-1627.
-
Foxman, S., Cameron, J.D.: The Clinical Implications of Bilateral Microphthalmos with Cyst: Report of a Fatal Case. Am. J. Ophthalmol. 1984;97:632-638.
-
Foxman, S., Heckenlively, J., Bateman, J., Wirtschafter, J.: A Classifications of Congenital and Early Onset Retinitis Pigmentosa. Arch. Ophthalmol. 1985;103:1502-1506.
-
Foxman, S., Heckenlively, J., Sinclair, S.: Pigmented Paravenous Retinochoroidal Atrophy and Rubeola Retinopathy. Am. J. Ophthalmol. 1985;99:605-606.
-
Fishman, M., Kerman, B., Foxman, S.: Intraocular Cysticercus: Migratory. Ossonig, K. (ed): Proceedings of the 10th SIDUO Congress, Netherlands, W. Junk, 1986.
-
Heckenlively, J., Foxman, S., Parelhoff, E.: Retinal Dystrophy and Macular Coloboma. Doc Ophthal. 1988:68:257-271. Shields, J., Perez, N., Shields, C., Foxman, S., Foxman, B.: Simultaneous Choroidal and Brain Metastasis as Initial Manifestations of Lung Cancer. Ophthalmic Surgery and Lasers. 2002:35:323-325.
-
Shields, J., Perez, N., Shields, C., Foxman, S., Foxman, B.: Simultaneous Choroidal and Brain Metastasis as Initial Manifestations of Lung Cancer. Ophthalmic Surgery and Lasers. 2002:35:323-325.
-
Foxman, S.: Finding the right fit: Considerations on both sides of the employment process. Retina Times. 2006: 24: 25-27.
-
Foxman, S.: Office Administrator: The guide of your practice’s success. Retina Times. 2006: 24: 47-51.
-
Ferencz L, Lang J, Yeshurn I, Pollack A, Siegel R, Lifshitz T, Karp J et al. Toward earlier detection of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2010 March.
-
Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY; CRUISE Investigators. Ranibizimab for macular edema following central retinal vein occlusion: six month primary end point results of phase III study. Ophthalmology. 2010 June; 117(6):1124-1133.e1.
EDITORIAL POSITION:
Research:
Principal and/or Sub-Investigator in over 35 National Clinical Studies Amgen 20170542 – Sub Investigator
Amgen Inc. and Parexel International LLC
February 2020 – Present
A Randomized, Double-masked, Phase 3 Study of ABP938 Efficacy and Safety Compared to Aflibercept (Eylea) in Subjects with Neovascular Age-related Macular Degeneration.
PANDA KHB-1802 – Sub-Investigator
Syneos Health, LLC
October 2019 – Present
A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration.
SAGA ALK001-P3001 – Sub-Investigator
Alkeus Pharmaceuticals, Inc.
October 2019 – Present
A Phase 2/3 Multicenter, Randomized, Double – masked, Parallel – group, Placebo- controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age – related Macular Dengeneration.
Yosemite GR40349 – Principal Investigate
F. Hoffmann-La Roche Ltd
July 2018 – Present
Phase III, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Evaluate the Efficacy and Safety of R06867461 in Patients with Diabetic Macular Edema
Aerpio AKB-9778-CI-5001 – Sub-Investigator
Aerpio Therapeutics LLC
August 2017 – Present
Phase III Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15MG Once Daily or 15MG Twice Daily for 12 Months in Patients with Moderate to Severe Non-Proliferative Diabetic Retinopathy.
Omaspect Extension Study of Spectri GX30191 – Principal Investigator
F. Hoffman-La Roche Ltd
March 2017 – Present
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study.
TOGA-01 Phase II/III – Principal Investigator
University of Virginia Department of Ophthalmology
February 2017 – Present
A Randomized, Double Masked, Placebo-Controlled Study Evaluating ORACEA® in Subjects with Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration.
MAKO-OHR-1601 / Chiltern Study Code No. 35544 – Sub-Investigator
OHR Pharmaceutical, Inc.
June 2016 – July, 2017
Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration.
Capella R2176-3-AMD-1417 – Sub-Investigator
Regeneron
September 2015 – September 2016
A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients with Neovascular Age-Related Macular Degeneration.
Spectri GX29185 – Principal Investigator
F. Hoffman-La Roche Ltd
August 2014 – Present
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study
to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to
Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration.
SCORE2 – Sub-Investigator
National Eye Institute, National Institutes of Health, Department of Health and
Human Services
March 2014-2015
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2): A
Multicenter, Prospective, Randomized, Phase III Non-Inferiority Trial of Eyes
with Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal
Bevacizumab Every 4 Weeks Versus Intravitreal aflibercept Every 4 Weeks.
ORBIT TG-MV-018 – Sub-Investigator
ThromboGenics, Inc.
February 2014-2015
A Multicenter, Prospective, Observational Phase 4 Study That Will Assess Clinical
Outcomes and Safety of Jetrea Administered in a Real-World Setting for the Treatment
of Symptomatic Vitreomacular Adhesion (VMA) by Assessing Anatomical and Functional
Outcomes in 1500 Patients Recruited Across Approximately 120 USA Retina Sites.
Eclipse OPH1002A – Principal Investigator
Ophthotech Corp
September 2013 – August 2016
A Phase III Randomized, Double-Masked, Controlled Trial to Establish the Safety and
Efficacy of Intravitreou s Administration of Fovista (Anti PDGF-B Pegylated Aptamer)
Administered in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects
Subjects with Subfoveal Neovascular Age-Related Macular Degeneration.
BAM 114341 – Sub-Investigator
Glaxo Smith Kline
March 2013-2015
A Phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled,
Parallel-Group Study to Investigate the Safety, Tolerability, Efficacy,
Pharmacokinetics and Pharmacodynamics of GSK933776 in Adult Patients with
Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).
VGFTe-AMD-1124 – Sub-Investigator
Regeneron
January 2013-2014
AAn Open-Label Study of the Efficacy, Safety and Tolerability of Intravitreal
Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients with
Neovascular Age-Related Macular Degeneration.
PROTOCOL S – Sub-Investigator
DRCR.net
July 2012-Present
Prompt Panretinal Photocoagulation versus Intravitreal Ranibizumab with
Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Protocol V - Sub-Investigator
DRCR.net
July 2012-Present
Treatment for Central Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity
VIBRANT – Sub-Investigator
Regeneron
June 2012-2013
Protocol: VGFT e-RVO -1027
A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety and
Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept
Injection(IAI) in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion
SAKURA-Principal Investigator
Santen Incorporated
2011-2013
Protocol No. 32-007:
A Phase III, Multinational, Multi-Center, Randomized, Double-Masked Study Assessing
the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the
Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye.
VISTA – Sub-Investigator
Regeneron
2011-2013
VGFT-OD-1009
A Double-Masked, Randomized, Active-Controlled Phase 3 Study of the Efficacy and
Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic
Macular Edema. PAREXEL #201601
SHORE-Principal Investigator
Genetech
2011-2013
BB-IND 8633-Protocol FVF4967g:
A Multi-Center Randomized Study Evaluating Dosing Regimens for Treatment with
Intravitreal Ranibizumab Injections in Subjects with Macular Edema Following
Retinal Vein Occlusion.
VIEW 1 EXTENSION - Sub-Investigator
Regeneron
2010-2012
Protocol: VGFT-OD-0910
Open-label, long-term, safety and tolerability extension study of intravitreal
VEGF Trap-Eye in neovascular age-related macular degeneration
NAION - Principal Investigator
Covance
2009-Present
Protocol: 12912
Prospective case crossover study to assess whether PDE5 inhibitor exposure in men
with erectile dysfunction increases the risk for the development of non-arteritic anterior
ischemic optic neuropathy (NAION).
COPERNICUS - Sub-Investigator
Regeneron
2009-April 2012
Protocol: VGFT-OD-0819
Randomized, double-masked, controlled phase III study of the efficacy, safety and
tolerability of repeated administration of VEGF Trap-Eye in subjects with macular edema
secondary to central retinal vein occlusion (CRVO).
HARBOR - Principle Investigator
Genentech
2009-2012
Protocol: FVF4579G
Phase III, double-masked, multi-center, randomized, active treatment, controlled study
of the efficacy and safety of 0.5 mg and 2.0 mg Ranibizumab; administered monthly
or on an as-needed basis (PRN) in patients with subfoveal neovascular
age-related macular degeneration.
RISE - Principal Investigator
Genentech
2008-2012
Protocol: FVF4170G
Three-year multi-center study with monthly visits for patients with diabetic macular
edema comparing Lucentis with Standard of Care Laser treatments.
CRUISE-Principal Investigator
Genentech
2008-2010
Protocol: FVF41669
One-year multi-center study with monthly visits comparing Lucentis to sham
procedure for patients with central retinal vein occlusion.
DAVINCI - Sub-investigator
Regeneron
2008-2010
Protocol: VGFT-OD-0706
A double-masked, randomized, controlled study of the safety, tolerability
and biological effect of repeated intravitreal administration of VEGF Trap-Eye in
patients with diabetic macular edema (DME).
HORIZON - Principal Investigator
Genentech
2008-2010
Protocol: FVF3426G
An open-label, multicenter extension study to evaluate the safety and
tolerability of ranibizumab in subjects with choroidal neovascularization (CNV)
secondary to age-related macular degeneration (AMD) or macular edema secondary to
retinal vein occlusion (RVO) who have completed a Genentech-sponsored ranizumab study.
VIEW1 - Sub-Investigator
Regeneron
Protocol: VGFT-OD-0605
Two-year multi-center study with monthly visits comparing VEGF-Trap against
Lucentis for patients with newly-diagnosed age-related macular degeneration.
SIRIUS - Sub-Investigator
Allergan
2006-2008
Protocol: 211745-001-01
Two-year multi-center study comparing Sirna against Lucentis for age-related
macular degeneration
NOTAL VISION HMP-V4 - Sub-Investigator
Notal Vision
2006-2007
Protocol: 20071801
Sensitivity of the Home Macular Perimeter (HMP) in
detection of choroidal neovascularization (CNV) secondary to
age-related macular degeneration (ARMD).
SAILOR-Principal Investigator
Genentech, Inc.
2003-2007
Protocol: FVF3689G
One-year multi-center study to evaluate the safety and tolerability
of Lucentis in newly-diagnosed and previously-treated subjects with
age-related macular degeneration.
Visudyne Photodynamic Therapy - Sub-Investigator
Ciba Vision
1999-2000
Clinical Investigator for Visudyne Photodynamic Therapy study.
Flibanserin - Sub-Investigator
University of Pennsylvania and Boehringer Ingelheim (BI Trial
No. 1997-1998)
Eight-week, double-blind, placebo-controlled Phase II study of various doses
of flibanserin and paroxetine in patients with Major Depressive Disorder.
Our role was to perform ophthalmic examinations to evaluate for potential ocular
complications and side effects.
Pioglitazone - Sub-Investigator
Takeda America, Inc.
1996
A double-blind placebo-controlled, randomized, dose-titration study to evaluate
the safety and efficacy of pioglitazone, an oral hypoglycemic agent. Our role was to
perform retinal examinations and evaluate retinal photographs for evidence of
diabetic retinopathy.
Adefovir Dipivoxil (bis-POM PMEA) - Sub-Investigator
NJCRI
1996-1997
A placebo-controlled study of the safety and efficacy of adefovir dipivoxil
(bis-POM PMEA) in prolonged survival of HIV-infected individuals with a CD4+
cell count of ≤ 100/mm3. Our role was for ophthalmic evaluation with emphasis
on the presence or absence of CMV retinitis.
Silicone Oil - Principal Investigator
Richard James Corporation
1993-1996
Principal Investigator. Clinical investigation as to the
utility and safety of silicone oil injection in the vitreous cavity
for patients with complicated retinal detachment. Our role was to
provide patient care including vitreoretinal surgery.
Perfluorocarbon Liquid - Principal Investigator
Retinal and Ophthalmic Consultants, P.C.
1992-1996
Clinical investigation as to the utility and safety of
intra-operative use of perfluorocarbon liquid into the vitreous
cavity during surgical reattachment of the retina.
Sulfur hexafluoride and Perfluoropropane - Sub-Investigator
Retinal and Ophthalmic Consultants, P.C.
1989-1994
Clinical investigation as to the utility and safety of long-acting
gases in the repair of retinal detachments.
Diabetic Retinopathy
National Institutes of Health
Early Treatment of Diabetic Retinopathy Study (ETDRS)
1984-1985
Dr. Scott Foxman was investigator in landmark national
collaborative randomized trial of laser treatment for diabetic retinopathy.
Publications
Original Papers
Click here for additional information regarding research studies and publications by Dr. Foxman.
